| UNIVERSITE DE LIEGE Patent applications |
| Patent application number | Title | Published |
|---|
| 20120090043 | TARGETS FOR RETROVIRUS ASSOCIATED DISEASES - The invention concerns an isolated complex comprising an HIV or HTLV protein and a human protein. Corresponding nucleic acids, vectors, host cells, host organisms, compositions, kits, medical uses, diagnostic uses, and methods of screening agents are also contemplated. Disclosed are 212 interactions between 19 retroviral proteins and 131 human proteins. | 04-12-2012 |
| 20120014983 | RECOMBINANT ALPHA-HEMOLYSIN POLYPEPTIDE OF STAPHYLOCOCCUS AUREUS, HAVING A DELETION IN THE STEM DOMAIN AND HETEROLOGOUS SEQUENCES INSERTED - It refers to a recombinant alpha-hemolysin polypeptide of | 01-19-2012 |
| 20110257126 | WATER SOLUBLE CURCUMIN COMPOSITIONS FOR USE IN ANTI-CANCER AND ANTI-INFLAMMATORY THERAPY - The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumour and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases. In a fifth aspect, the present invention relates to the use of a pharmaceutical composition comprising said water soluble curcumin derivatives in the treatment of cancer and inflammatory diseases and to a new pharmaceutical composition comprising said water soluble curcumin derivatives. | 10-20-2011 |
| 20110006011 | METHOD FOR THE ELUTION OF 18F FLUORIDE TRAPPED ON AN ANION-EXCHANGE PHASE IN A FORM SUITABLE FOR EFFICIENT RADIOLABELING WITHOUT ANY EVAPORATION STEP - A method extracts out of an aqueous solution, concentrate and/or reformulate [18F] fluorides without any evaporation step. The eluting solution is a low water content, preferably <3% water, organic solution containing at least:
| 01-13-2011 |
| 20100287625 | VEGF VARIANTS - This invention relates to a Vascular Endothelial Growth Factor (VEGF) polypeptide, which polypeptide lacks an amino acid sequence encoded by exon 5 of the VEGF gene. This variant of VEGF is capable of eliciting activities associated with VEGF whilst showing resistance to proteolytic degradation. The invention provides uses of this protein and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease. | 11-11-2010 |
| 20100243972 | METHOD FOR THE PREPARATION OF REACTIVE [18] F FLUORIDE - The present invention is related to a method to obtain reactive [18F] fluorides in an organic medium suitable for radiolabelling without any azeotropic evaporation step, by the use of a solid phase extraction column containing a modified non-ionic solid support. | 09-30-2010 |
| 20100196926 | Combined Method And Kit For The Sequential Measurement of (1) The Enzymatically Active Fraction And (2) The Total Amount Of An Enzyme - The present invention is related to a combined method and kit (or device) for the sequential measurement of the enzymatically active fraction and the total amount of an enzyme [(such as myeloperoxidase (MPO)] in a sample, and that find improved applications in veterinary and human health fields. | 08-05-2010 |
| 20100196254 | METHOD FOR THE DIRECT ELUTION OF REACTIVE 18F FLUORIDE FROM AN ANION EXCHANGE RESIN IN AN ORGANIC MEDIUM SUITABLE FOR RADIOLABELLING WITHOUT ANY EVAPORATION STEP BY THE USE OF STRONG ORGANIC BASES - A method to extract out of an aqueous solution, concentrate and/or reformulate [18F] fluorides without any evaporation step wherein the eluting solution is a organic solution having a water content <3%. The solution contains at least: an organic solvent suitable for the subsequent radiolabelling reaction; a first compound (A) which is a molecule containing at least one acidic hydrogen and a second compound (B) which is an organic base sufficiently strong to be able to tear off the acidic hydrogen of the first compound (A) in an acid-base reaction leading to the formation of an organic salt (S). | 08-05-2010 |
| 20100137240 | USE OF NUCLEOSIDE DERIVATIVES AS ANTI-KOI HERPES VIRUS IN FISH - The present invention relates to the use of N-phosphonylmethoxyethyl nucleoside analogs for manufacturing a medicament for the treatment or prevention of Koi Herpes virus infections in fish, especially in carps. | 06-03-2010 |
| 20100136543 | METHOD FOR DETERMINING THE GENOTYPE AT THE CROHN'S DISEASE LOCUS - The present invention refers to a method for determining the genotype of an individual at the 5p13.1 Crohn's disease risk locus, the method comprising: providing a sample from the individual; determining whether a DNA sequence corresponding to a DNA sequence polymorphism located between coordinated 40,300,000 and 40,600,000 of human chromosome (coordinates corresponding to the march 2006 assembly of the human genome) is present in the sample; and determining the nature of the DNA sequence polymorphism genotype located between coordinated 40,300,000 and 40,600,000 of human chromosome as it relates to the genetic risk to develop Crohn's disease. | 06-03-2010 |
| 20100080978 | POLYMER COMPOSITE MATERIAL STRUCTURES COMPRISING CARBON BASED CONDUCTIVE LOADS - The present invention provides a polymer composite material structure comprising at least one layer of a foamed polymer composite material comprising a foamed polymer matrix and 0.1 wt % to 6 wt % carbon based conductive loads, such as e.g. carbon nanotubes, dispersed in the foamed polymer matrix. The polymer composite material structure according to embodiments of the present invention shows good shielding and absorbing properties notwithstanding the low amount of carbon based conductive loads. The present invention furthermore provides a method for forming a polymer composite material structure comprising carbon based conductive loads. | 04-01-2010 |
| 20090093517 | BIS1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR USES AS PHARMACEUTICALS - Use of Bis 1,2,3,4-tetrahydroisoquinoline derivatives represented by formula (I) | 04-09-2009 |
| 20090042220 | Method for monitoring collagen type II degradation in cartilage - A method for improving the diagnostic assessment of cartilage degenerative processes, and to provide means of monitoring the effects of therapeutical measures taken towards arthritic diseases in most mammals utilizes an immunoassay to detect fragments of collagen type II resulting from collagenase activity comprising an antibody directed against an epitope comprised in the amino acid sequence HRGYPGLDG (SEQ ID NO:1), located in the helical region of collagen type II. | 02-12-2009 |
| 20080293630 | Mucoadhesive Pharmaceutical Compositions Comprising Chemoattractants - The invention relates to a mucoadhesive pharmaceutical composition comprising a polymer and a chemoattractant wherein the pH of the composition is greater than 6 which is useful in the treatment of a anogenital or oral disease, particularly an anogenital or oral disease cause by the human papillomavirus. | 11-27-2008 |
| 20080274085 | Probiotic Bifidobacterial Species - A probiotic composition comprising a | 11-06-2008 |
| 20080233600 | Method and Kit for the Measurement of Neutrophil Cell Activation - The present invention is related to accurate detection methods for the measurement only of myelopexidase (MPO) levels or neutrophils, preferably equine neutrophils, in complex biological samples. The present invention is further related to ELISA and SIEFED assays for such detection. SIEFED detection sensitivity of active peroxidase activity was found to be enhanced by the addition of nitrite. Such MPO measurement finds its use in many applications such as the prediction, diagnosis and/or monitoring of pathologies correlated with neutrophil activation and/or destruction; the evaluation of drugs and/or immunomodulators; the assessment of immune responses, either natural and/or after treatment with immunomodulators and/or drugs; and the study of cells and their ability to fight microorganisms and/or to destroy them. | 09-25-2008 |
